Kumar A Aravin, Lee Sean Wei Yee, Lock Christine, Keong Nicole Ch
Department of Neurosurgery, National Neuroscience Institute, Singapore, Singapore.
Tan Tock Seng Hospital, Singapore, Singapore.
Front Med (Lausanne). 2021 Apr 29;8:661359. doi: 10.3389/fmed.2021.661359. eCollection 2021.
The novel coronavirus disease (COVID-19), has become the most critical global health challenge in recent history. With SARS-CoV-2 infection, there was an unexpectedly high and specific prevalence of olfactory and taste disorders (OTDs). These high rates of hyposmia and hypogeusia, initially reported as up to 89% in European case series, led to the global inclusion of loss of taste and/or smell as a distinctive feature of COVID-19. However, there is emerging evidence that there are striking differences in the rates of OTDs in East Asian countries where the disease first emerged, as compared to Western countries (15.8 vs. 60.9%, -value < 0.01). This may be driven by either variations in SARS-CoV-2 subtypes presenting to different global populations or genotypic differences in hosts which alter the predisposition of these different populations to the neuroinvasiveness of SARS-CoV-2. We also found that rates of OTDs were significantly higher in objective testing for OTDs as compared to subjective testing (73.6 vs. 60.8%, -value = 0.03), which is the methodology employed by most studies. Concurrently, it has also become evident that racial minorities across geographically disparate world populations suffer from disproportionately higher rates of COVID-19 infection and mortality. In this mini review, we aim to delineate and explore the varying rates of olfactory and taste disorders amongst COVID-19 patients, by focusing on their underlying geographical, testing, ethnic and socioeconomic differences. We examine the current literature for evidence of differences in the olfactory and gustatory manifestations of COVID-19 and discuss current pathophysiological hypotheses for such differences.
新型冠状病毒病(COVID-19)已成为近代以来最严峻的全球健康挑战。感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)后,嗅觉和味觉障碍(OTD)的患病率出奇地高且具有特异性。这些嗅觉减退和味觉减退的高发生率,最初在欧洲病例系列中报告高达89%,导致全球将味觉和/或嗅觉丧失列为COVID-19的一个显著特征。然而,新出现的证据表明,与西方国家相比,该疾病最初出现的东亚国家OTD发生率存在显著差异(15.8%对60.9%,P值<0.01)。这可能是由于呈现给不同全球人群的SARS-CoV-2亚型存在差异,或者宿主的基因型差异改变了这些不同人群对SARS-CoV-2神经侵袭性的易感性。我们还发现,与主观测试相比,OTD客观测试中的OTD发生率显著更高(73.6%对60.8%,P值=0.03),而大多数研究采用的是主观测试方法。与此同时,显而易见的是,世界各地不同地理区域的少数族裔感染COVID-19和死亡的比例过高。在这篇小型综述中,我们旨在通过关注COVID-19患者潜在的地理、测试、种族和社会经济差异,来描述和探索嗅觉和味觉障碍的不同发生率。我们查阅了当前文献,以寻找COVID-19嗅觉和味觉表现存在差异的证据,并讨论了造成这种差异的当前病理生理假设。